1.36  0.01 (0.74%)		09-06 15:59
Open: 1.32 High: 1.36 Volume: 22,668		Pre. Close: 1.35 Low: 1.31 Market Cap: 5(M)

Short term
Mid term
Targets	6-month :	0.94	1-year :	1.07
Resists	First :	0.8	Second :	0.92
Pivot price	0.69
Supports	First :	0.61	Second :	0.51
MAs	MA(5) :	0.66	MA(20) :	0.69
	MA(100) :	1.15	MA(250) :	2.62
MACD	MACD :	-0.1	Signal :	-0.1
%K %D	K(14,3) :	27.6	D(3) :	23.7
RSI	RSI(14): 39.6
52-week	High :	11.48	Low :	0.61

Price has closed above its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BEARISH in mid-long term.
[ BVXV ] has closed above bottom band by 39.1%. Bollinger Bands are 29.6% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.

If tomorrow:	Open lower	Open higher
High:	0.7 - 0.7	0.7 - 0.71
Low:	0.65 - 0.66	0.66 - 0.66
Close:	0.66 - 0.67	0.67 - 0.67

BiondVax Pharmaceuticals Ltd., a development stage biopharmaceutical company, focuses on developing, manufacturing, and commercializing products for the prevention and treatment of infectious diseases and other illnesses in Israel. The company has licensing and collaboration agreement with Max Planck Society and University Medical Center Göttingen for the development and commercialization of COVID-19 nanosized antibody (NanoAb); and development and commercialization of NanoAbs for various other disease indications. The company was incorporated in 2003 and is headquartered in Jerusalem, Israel.

Wed, 06 Sep 2023
Press Release dated September 6, 2023, “BiondVax Pharmaceuticals Ltd. Rebrands as Scinai Immunotherapeutics Ltd ... - SEC.gov

Wed, 12 Jul 2023
BiondVax bets on alpacas to treat psoriasis - Globes

Fri, 30 Sep 2022
BiondVax announces financial plans to support its ongoing NanoAb pipeline development - BioSpace

Sun, 25 Oct 2020
Biondvax plunges on failed universal flu vaccine trial - Globes

Fri, 23 Oct 2020
BiondVax Announces Topline Results from Phase 3 Clinical Trial of the M-001 Universal Influenza Vaccine Candidate - BioSpace

Tue, 16 Jul 2019
BiondVax Announces Rights Offering Fully Subscribed at US$20 Million - BioSpace

Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.	Underperform
Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).	Neutral
Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.	Outperform
Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.	Underperform
Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.	Outperform
Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.	Underperform

Exchange: NASDAQ
Sector: Healthcare
Industry: Biotechnology
Shares Out	4 (M)
Shares Float	3 (M)
Held by Insiders	20 (%)
Held by Institutions	10.6 (%)
Shares Short	5 (K)
Shares Short P.Month	5 (K)

EPS	-2.35
EPS Est Next Qtrly	0
EPS Est This Year	0
EPS Est Next Year	0
Book Value (p.s.)	-1.97
Profit Margin	0 %
Operating Margin	0 %
Return on Assets (ttm)	-30.9 %
Return on Equity (ttm)	0 %
Qtrly Rev. Growth	0 %
Gross Profit (p.s.)	0
Sales Per Share	0
EBITDA (p.s.)	-2.85
Qtrly Earnings Growth	0 %
Operating Cash Flow	-8 (M)
Levered Free Cash Flow	-10 (M)

PE Ratio	-0.29
PEG Ratio	0
Price to Book value	-0.35
Price to Sales	0
Price to Cash Flow	-0.3

Dividend	0
Forward Dividend	0
Dividend Yield	0%
Dividend Pay Date	Invalid DateTime.
Ex-Dividend Date	Invalid DateTime.